Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$73.37 USD

73.37
57,611

+0.55 (0.76%)

Updated Apr 26, 2024 11:03 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 20.93% and 3.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Align Technology (ALGN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of 8.08% and 2.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.

Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay

by Zacks Equity Research

Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).

Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space

by Zacks Equity Research

According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.

Why Is Henry Schein (HSIC) Down 1.8% Since Last Earnings Report?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Compared to Estimates, Henry Schein (HSIC) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down

by Zacks Equity Research

Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.

Henry Schein (HSIC) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of -5.71% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Seeking Clues to Henry Schein (HSIC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Henry Schein (HSIC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.

Henry Schein (HSIC) Sales Hurt by Cyber Attack, Macro Woes

by Zacks Equity Research

Henry Schein's (HSIC) financial operations are being affected by the current macroeconomic environment.

Henry Schein (HSIC) Enters Orthopedic Market With New Buyout

by Zacks Equity Research

Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.

Henry Schein (HSIC) Up 4.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal

by Zacks Equity Research

Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.

Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut

by Zacks Equity Research

Henry Schein's (HSIC) third-quarter 2023 performance demonstrates remarkable sales growth in the Technology and Value-Added Service businesses.

Compared to Estimates, Henry Schein (HSIC) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Henry Schein (HSIC) Matches Q3 Earnings Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 0% and 0.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Insights Into Henry Schein (HSIC) Q3: Wall Street Projections for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Henry Schein (HSIC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.

Cardinal Health (CAH) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 23.57% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Henry Schein (HSIC) Set to Post Q3 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) third-quarter 2023 results are likely to reflect the strong fundamentals of the Dental business.

Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare

by Zacks Equity Research

Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.